Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma
Abstract This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-84047-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841544835978231808 |
---|---|
author | Kaili Chen Huixin Liang Zezhong Yu Guangyao Guo Huijian Zheng Yun Huang Liping Liu Jie Lin Jinlan Long Renyao Pan Xi Chen Changgui Wang Wenjie Zhang Zhenshu Xu |
author_facet | Kaili Chen Huixin Liang Zezhong Yu Guangyao Guo Huijian Zheng Yun Huang Liping Liu Jie Lin Jinlan Long Renyao Pan Xi Chen Changgui Wang Wenjie Zhang Zhenshu Xu |
author_sort | Kaili Chen |
collection | DOAJ |
description | Abstract This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function and hemoglobin recovery), immune reconstitution (B-cell subsets, immunoglobulin levels, T-cell subsets, NK cells, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR)) and hematopoietic reconstitution times were collected and analyzed. Whether in all selected patients or in groups R-ISS II-III, there was a notable increase in the proportion of patients achieving in a very good partial response (VGPR) or better (P < 0.001, P = 0.02) and a complete response (CR) or better (P = 0.007, P = 0.014) after transplantation compared to the pre-transplant status. Post-Transplant Immune Reconstitution Analysis (Baseline vs. Pre-Transplant and Pre-Transplant vs. Post-Transplant): The level of CD19 + B cells, CD20 + B cells, CD22 + B cells, CD3 + T cells, IgG and LMR showed the same change trend, that is, it decreased before transplantation (P < 0.001, P < 0.001, P < 0.001, P < 0.001, P<0.007, P < 0.001) and then increased significantly after transplantation(P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001). CD3 + CD4 + T cells from 545.97 (342.11,708.60)/µL to 342.93 (168.38, 475.52)/µL (P < 0.001) and then to 251.48 (188.52, 406.98)/µL (P = 0.348); CD3 + CD8 + T cells from 391.36 (242.19, 563.37)/µL to 337.23 (192.54, 505.96)/µL (P = 0.065) and then to 797.96 (514.49, 1198.03)/µL (P < 0.001), so the CD3 + CD4+/CD3 + CD8 + T cell ratio still remained inverted post-transplant. NK cells changed from 309.86 (206.33, 460.96)/µL to 258.31 (160.75, 436.68)/ µL (P = 0.229) and then to 151.08 (108.17, 240.84)/µL (P = 0.007). Auto-HSCT can promote prolonged remission in patients with MM and also overcome some high-risk factors to achieve superior efficacy in group R-ISS II-III. Patients were immunodeficient before transplantation and auto-HSCT facilitated immune reconstitution. |
format | Article |
id | doaj-art-a2b4c969b5dc4be480bc8d2e00a00bc5 |
institution | Kabale University |
issn | 2045-2322 |
language | English |
publishDate | 2025-01-01 |
publisher | Nature Portfolio |
record_format | Article |
series | Scientific Reports |
spelling | doaj-art-a2b4c969b5dc4be480bc8d2e00a00bc52025-01-12T12:14:53ZengNature PortfolioScientific Reports2045-23222025-01-0115111210.1038/s41598-024-84047-2Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myelomaKaili Chen0Huixin Liang1Zezhong Yu2Guangyao Guo3Huijian Zheng4Yun Huang5Liping Liu6Jie Lin7Jinlan Long8Renyao Pan9Xi Chen10Changgui Wang11Wenjie Zhang12Zhenshu Xu13Department of Blood Transfusion, Affiliated Hospital of Putian UniversityDepartment of infectious diseases, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union HospitalAbstract This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function and hemoglobin recovery), immune reconstitution (B-cell subsets, immunoglobulin levels, T-cell subsets, NK cells, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR)) and hematopoietic reconstitution times were collected and analyzed. Whether in all selected patients or in groups R-ISS II-III, there was a notable increase in the proportion of patients achieving in a very good partial response (VGPR) or better (P < 0.001, P = 0.02) and a complete response (CR) or better (P = 0.007, P = 0.014) after transplantation compared to the pre-transplant status. Post-Transplant Immune Reconstitution Analysis (Baseline vs. Pre-Transplant and Pre-Transplant vs. Post-Transplant): The level of CD19 + B cells, CD20 + B cells, CD22 + B cells, CD3 + T cells, IgG and LMR showed the same change trend, that is, it decreased before transplantation (P < 0.001, P < 0.001, P < 0.001, P < 0.001, P<0.007, P < 0.001) and then increased significantly after transplantation(P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001). CD3 + CD4 + T cells from 545.97 (342.11,708.60)/µL to 342.93 (168.38, 475.52)/µL (P < 0.001) and then to 251.48 (188.52, 406.98)/µL (P = 0.348); CD3 + CD8 + T cells from 391.36 (242.19, 563.37)/µL to 337.23 (192.54, 505.96)/µL (P = 0.065) and then to 797.96 (514.49, 1198.03)/µL (P < 0.001), so the CD3 + CD4+/CD3 + CD8 + T cell ratio still remained inverted post-transplant. NK cells changed from 309.86 (206.33, 460.96)/µL to 258.31 (160.75, 436.68)/ µL (P = 0.229) and then to 151.08 (108.17, 240.84)/µL (P = 0.007). Auto-HSCT can promote prolonged remission in patients with MM and also overcome some high-risk factors to achieve superior efficacy in group R-ISS II-III. Patients were immunodeficient before transplantation and auto-HSCT facilitated immune reconstitution.https://doi.org/10.1038/s41598-024-84047-2Multiple myelomaAutologous hematopoietic stem cell transplantationEfficacy analysisImmune reconstitution |
spellingShingle | Kaili Chen Huixin Liang Zezhong Yu Guangyao Guo Huijian Zheng Yun Huang Liping Liu Jie Lin Jinlan Long Renyao Pan Xi Chen Changgui Wang Wenjie Zhang Zhenshu Xu Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma Scientific Reports Multiple myeloma Autologous hematopoietic stem cell transplantation Efficacy analysis Immune reconstitution |
title | Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma |
title_full | Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma |
title_fullStr | Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma |
title_full_unstemmed | Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma |
title_short | Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma |
title_sort | analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma |
topic | Multiple myeloma Autologous hematopoietic stem cell transplantation Efficacy analysis Immune reconstitution |
url | https://doi.org/10.1038/s41598-024-84047-2 |
work_keys_str_mv | AT kailichen analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT huixinliang analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT zezhongyu analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT guangyaoguo analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT huijianzheng analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT yunhuang analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT lipingliu analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT jielin analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT jinlanlong analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT renyaopan analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT xichen analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT changguiwang analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT wenjiezhang analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT zhenshuxu analysisofearlyefficacyandimmunereconstitutionafterautologoushematopoieticstemcelltransplantationinmultiplemyeloma |